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The normal human breast is responsive to the ovarian steroid
hormones oestrogen and progesterone and it is an essential feature
of breast cancer that this hormone responsive character is
frequently retained. The effects of oestrogen and progesterone are
mediated by specific nuclear receptors, ER and PR. Expression of
these receptors in breast tumours is associated with a number of
favourable pathological features such as smaller tumour size, low
tumour cell proliferation rates and low grade (Thorpe, 1988;
Wenger et al, 1993), and consistent with this, an association
between improved clinical outcome and receptor positivity has
been reported (Pichon et al, 1996). This evidence suggests that the
pattern of expression of ER and PR in breast cancer is associated
with tumour subtypes which are clinically and also pathologically
distinct.
The expression of ER and PR in breast cancer is a useful clinical
marker of likely response to therapeutic endocrine agents
(Horwitz, 1981; McGuire et al, 1991) and these receptors are
therefore routinely assayed in clinical breast cancer specimens. In
addition, the combined ER/PR profile of a tumour gives insight
into aspects of receptor function and stimulation as the expression
of PR is induced by oestrogenic stimulation of ER and, therefore,
not only signals potential progesterone sensitivity, but also
becomes a marker of a functioning oestrogen response pathway
(Horwitz et al, 1975; Horwitz and McGuire, 1978; Clarke, 1993).
Although the predictive value of receptor status in response to
endocrine agents is well established, the relationship between
expression of ER and PR and tumour progression is less clear. It is
not known whether tumours arise from cells with a specific
receptor phenotype, for instance ER+PR+, and progressively lose
first one then the other of these receptors, and receptors for other
endocrine agents to eventually become receptor negative, or
whether the receptor phenotype is stable as the disease progresses,
with the worsening clinical course being consequent to other
genetic and biological alterations.
A large number of studies have examined receptor expression in
primary and secondary breast cancers, the majority of which have
used biochemical assays of ER and, less frequently, PR. In
general, studies on metastatic breast cancer have been limited by
the low frequency with which such lesions are biopsied, so the
numbers in studies published to date are limited. The trend is for
the receptor phenotype of the primary and secondary tumours to
be the same, although the data are complicated by the range of
discordant results (Webster et al, 1978; Hoehn et al, 1979; Allegra
et al, 1980; Parideans et al, 1980; Peetz et al, 1982; Harland et al,
1983; Hull et al, 1983; Gross et al, 1984; Jakesz et al, 1985;
Raemakers et al, 1984; Alanko, 1985; Hahnel and Twaddle, 1985;
Crawford et al, 1987, Butler et al, 1989; Spataro et al, 1992). This
is probably due both to the small size of the majority of studies, as
mentioned above, and to the limitations of the biochemical assays,
which include admixture of non-malignant and malignant cells
and the possibility that receptors bound by endogenous or pharma-
cological ligands are likely to be missed in ligand-binding assays
of tumour receptor content (Hull et al, 1983; Encarnacion et al,
1993). More recent reports have overcome these limitations by
using immunohistochemical determination of ER and PR, but the
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numbers examined are small. Nevertheless, it appears that in
matched cases the receptor phenotype of the primary cancer is
likely to be maintained in the recurrent tumour in the majority of
cases (Kamby et al, 1989; Muller-Holzner et al, 1993; Kuukasjarvi
et al, 1996). The more general question of whether certain receptor
phenotypes are associated with greater likelihood of progression to
metastasis is, therefore, important.
The purpose of this study was to determine, using immunocyto-
chemical methods in a large cohort of primary and secondary
breast cancers sampled by fine needle aspiration, the combined ER
and PR phenotypes, to ask whether secondary lesions are more
likely to be receptor-positive than negative and to determine
whether a particular ER/PR phenotype predominated in secondary
lesions. The profile of receptor expression in primary and
secondary tumours in pre- and postmenopausal women is not
known and has also been examined in this study.
METHODS
Patients
Patients were women who presented for diagnostic fine needle
aspiration biopsies of breast tumours to the Department of Tissue
Pathology at Westmead Hospital between 1986 and 1993.
‘Primary’ tumours were aspirates of lesions in the breast diag-
nosed as ‘adenocarcinoma’ or ‘colloid carcinoma’. ‘Secondary’,
tumours were included if the clinical details provided with the
request form included a history of primary breast cancer, if there
had been a previous breast aspirate or if the cytological report
included a comment that the appearances were consistent with
origin in breast. One additional postmenopausal patient, not
meeting these criteria but with cytological and clinical features
consistent with breast cancer, was also included. The ‘secondary’
tumours were diagnosed as ‘metastatic adenocarcinoma’, ‘colloid
carcinoma’ or ‘adenocarcinoma’ and comprised chest wall recur-
rences as well as deposits in regional lymph nodes, skin and
soft tissue and some visceral sites reflecting the accessibility of
these to fine needle aspiration. Regional lymph node deposits
contributed the largest proportion.
The cohort consisted of 807 patients from whom 927 separate
fine needle aspiration biopsies of breast cancer were taken and
tested for the presence of one or both receptors. The age of the
patient was known at the time of 916 of these assays and ranged
from 25 to 100 years. The mean age was 58.7 years. The mean age
of patients with primary tumours was 59 years and secondary
tumours was 57 years. In order to gauge the effect of menopausal
status, women who were 50 years of age or younger at the time of
the test were designated ‘premenopausal’ and those over 50 years
of age, ‘postmenopausal’. The mean age of premenopausal patients
with primary tumours was 43 years and 42 years for those with
secondary lesions. The mean age of postmenopausal women with
primary tumours was 67 years and 66 years for secondary cases.
In total there were 912 ER assays, 689 from primary tumours
and 223 from secondaries, available for analysis. There were 564
PR results: 443 of these were from primary tumours and 121 from
secondary deposits.
Assays performed on simultaneous aspirates from primary
tumours and regional lymph node metastases were compared also.
For this analysis, patients were taken from the previously
described cohort, with additional cases sampled between 1993 
and 1996 included to increase patient numbers. There were 88
simultaneous ER assays available for analysis and 65 cases with
simultaneous PR results.
Detection of ER and PR in fine needle aspirates by
immunocytochemistry
Fine needle aspirates of breast tumours and immunocytochemical
receptor determinations were performed in the Department of
Tissue Pathology at Westmead Hospital as has previously been
described (Greenberg et al, 1989). Briefly: aspirated material was
fixed in freshly prepared 10% formalin in 0.01 M phosphate-
buffered saline (PBS), at 4°C for 10–30 min after which time four
cytospin slides were prepared. Chrome alum-gelatin coated slides
were used to improve cell adhesion. The slides were then stored in
chilled storage medium at –10°C to –20°C for up to 4 months.
Prior to staining, a test and control slide were rinsed in two
changes of PBS pH 7.3 for 10 min to remove storage medium. The
slides were placed in 100% methanol at –15°C for 5 min followed
by acetone at –15°C for 3 min. The slides were rinsed in PBS.
Immunostaining was performed using the Abbott ER-ICA and
PgR-ICA kits (Abbott Laboratories, Diagnostics Division, USA),
according to the manufacturer’s instructions. A positive control
Table 1 Multivariate analysis of the relationship between receptor
expression, menopausal status and primary versus secondary tumour site
Odds ratio 95% CI P-value
ER
Postmenopausal (> 50 years) 2.5 1.4–4.4 0.002
PR-positive 62.5 34.3–113.9 < 0.001
Primary site 1.0 0.6–1.8 0.956
PR
Premenopausal (≤ 50 years) 2.7 1.5–4.9 0.001
ER-positive 63.3 34.6–116.0 < 0.001
Primary site 2.7 1.4–5.0 0.002
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Figure 1 ER and PR content of primary and secondary breast cancer (n n):
primary tumours, ( ): secondary tumours). In both instances the difference
between primary and secondary cases was statistically significant, (c2 ER:
P = < 0.001, PR: P = < 0.001). ER primary n = 689, secondary n = 223. PR
primary n = 443, secondary n = 121)1566 RL Balleine et al
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was included in each staining run and negative controls comprised
a slide from each case in which the primary antibody was substi-
tuted with normal rat antibody supplied with the kit.
Immunocytochemical smears were evaluated by light
microscopy at ´ 400 magnification. A minimum of 200 tumour
cell nuclei were counted and cases were designated ‘unsatisfac-
tory’ if fewer cells were available for assessment. A scoring
system from 0 to 6, which combined the percentage of nuclei
stained and an estimate of the predominant nuclear staining inten-
sity, was used to report results (Greenberg et al, 1989). On the
basis of previous comparisons of immunocytochemical score and
assays of receptor content in breast tumour cytosol preparations
(Greenberg et al, 1989; MJ Earl, unpublished observations), scores
of 0, 1 or 2 were regarded as ‘negative’ and scores of 3 or higher as
‘positive’. For ER and PR in both primary and secondary tumours
over 90% of cases designated ‘negative’ had immunocytochemical
scores of 0.
Statistical methods
Chi-squared tests were performed using Abacus Concepts,
StatView Student software (Abacus Concepts Inc., Berkeley, CA,
USA). For simultaneously sampled primary and regional lymph
node metastases, the McNemars test was used to test whether the
distribution of discordant cases, between instances where the
primary tumour was receptor-positive and the secondary was
recepter-negative and vice versa, was significantly different from
random. The McNemars test was done using ARCUS Professional
version 1.00S software (© Iain Buchan 1990). The multivariate
analysis was done using SPSS for Windows, Release 5.0.1, statis-
tical analysis software.
RESULTS
ER and PR in primary and secondary breast cancer
Overall, 63.3% of primary tumours were ER-positive compared
with 45.3% of secondary tumours and 53.7% of primaries were
PR-positive compared with 33.1% of secondaries (Figure 1). In
both instances, c2 tests showed the difference between the primary
and secondary tumour groups to be highly statistically significant.
The data show that secondary lesions are significantly less likely
to contain receptors, suggesting either that primary tumours
lacking receptors are more likley to metastasize or, a less likely
explanation based on published studies, that receptor-positive
primaries become receptor-negative on disease progression.
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Figure 2 ER and PR content of primary and secondary breast cancer:
effect of menopausal status (n n: premenopausal primary tumours,  :
premenopausal secondary tumours,  : postmenopausal primary tumours,
: postmenopausal secondary tumours). In both age groups, primary
tumours were more likely to be ER-positive than secondary tumours, (c2
premenopausal P = 0.005, postmenopausal P = < 0.001). In premenopausal
patients, there was no significant difference in PR status between primary
and secondary tumours, whereas in postmenopausal patients secondary
tumours were more likely to be PR-negative (c2 premenopausal P = 0.178,
postmenopausal P = < 0.001). Premenopausal primary ER n = 227, 
PR n = 151. Premenopausal secondary ER n = 78, PR n = 46. Postmeno-
pausal primary ER n = 453, PR n = 287. Postmenopausal secondary 
ER n = 144, PR n = 74
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Figure 3 Combined ER and PR phenotype according to menopausal status
( : primary tumours,  : secondary tumours). Premenopausal primary
n = 148, secondary n = 43. Postmenopausal primary n = 281, secondary
n = 72PR absence in postmenopausal secondary breast cancer 1567
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Effect of menopausal status on hormone receptor
expression
The cohort was subdivided into women 50 years of age and
younger and those over the age of 50 in order to gauge the effect 
of menopausal status (Figure 2). Amongst older women, 66.9% 
of primary tumours were ER-positive compared with 48.6% of
secondary deposits. In the younger patient subgroup, 56.8% 
of primary tumours were ER-positive compared with 38.5% of
secondary lesions. Overall, older women were more likely to have
ER-positive tumours. In both age groups, by c2 analysis, primary
tumours were significantly more likely to be ER-positive than
secondaries.
In contrast, primary tumours from younger women showed
slightly higher rates of PR positivity than those from older women.
Although there was a modest drop in the rate of PR expression in
secondary tumours compared with primaries in the younger
patient subpopulation, from 57.0% to 45.7%, this did not achieve
statistical significance. In older patients, however, the rate of PR
expression was markedly lower in secondary tumours, only 24.3%
of cases being positive compared with 52.3% of primaries.
Examination of the combined expression of ER and PR revealed
that the most common receptor phenotypes were a presence or
absence of both receptors, illustrating the fact that the expression of
ER and PR were closely related to each other. When the population
was subdivided into pre- and postmenopausal patients, striking
differences in the profiles of ER and PR expression in primary 
and secondary tumours were revealed (Figure 3). Amongst
premenopausal women, ER/PR phenotypes were similar in primary
and secondary lesions. In the postmenopausal subgroup, primary
tumours were predominantly ER+PR+ and there was a marked
drop in the incidence of this receptor phenotype amongst secondary
tumours which was accounted for not only by an increase in the
number of ER–PR– cases but also a relative increase in ER+ PR–
cases. Thus secondary tumours from older women were usually
PR–, even if ER expression was retained.
The observation that there was a specific lack of PR expression
in the secondary tumours of postmenopausal women was tested by
multivariate analysis including receptor status, menopausal status
and whether a tumour was primary or secondary (Table 1). When
these variables were taken into account, with respect to ER it was
found that postmenopausal patients were more likely to have ER-
positive tumours and ER expression was closely related to the
presence of PR such that the odds of having an ER-positive
tumour were almost 63 times higher if PR was present. However,
when corrected for age and PR status, there was no longer a signi-
ficant difference between the rates of ER positivity in primary 
and secondary tumours (P = 0.956). In the analysis of PR,
premenopausal patients were more likely to have PR-positive
tumours and again the strong relationship between ER and PR
expression was demonstrated. Importantly, however, PR expres-
sion was still significantly more common in primary than
secondary tumours even when age and ER status were taken into
account (P = 0.002).
Simultaneous receptor assays on primary tumours and
corresponding regional lymph node metastases
In order to determine whether the lower rates of expression of ER
and PR in secondary with respect to primary tumours (Figures 1
and 2) reflected loss or alteration of receptor phenotype upon
progression to a metastatic site in this patient cohort, the receptor
content of primary tumours and simultaneously sampled corre-
sponding regional lymph node metastases were compared.
For ER, 88 cases were available for analysis (Figure 4). In 81
(92%) of these the ER status of both the primary and metastatic
tumour were the same. There were five cases (5.7%) of ER+
primaries associated with ER– metastases and two cases (2.3%)
where the primary was ER– but the lymph node deposit ER+. On
the basis of these results there was no evidence that ER expression
was systematically lost with progression from a primary to a
metastatic site (McNemars test, P = 0.3).
In respect of PR, there were 65 cases available for study (Figure
4). In 61 (93.8%) of these there was concordance between the PR
status of the primary tumour and the regional lymph node metas-
tasis. The four discordant cases were all PR+ primaries associated
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with PR– metastases. Thus 4/27 (14.8%) of PR+ primary tumours
were associated with PR– metastases (McNemars test, P = 0.045).
There was some evidence therefore that, although PR status was
consistent in primary and metastatic lesions, in a small number of
cases PR expression may be lost with progression to a metastatic
site. When this cohort was subdivided into patients under or over the
age of 50 years, two of the discordant cases fell into each category.
In order to investigate whether the specific lack of PR in metas-
tases from postmenopausal women (Figure 3, Table 1) arose in the
context of an alteration in the combined ER/PR phenotype upon
progression to a metastatic site, combined ER and PR status was
compared in 62 corresponding primary tumours and metastases
(Figure 5). The concordance between primary and secondary
tumours was high, with the same receptor phenotype being found
in 56 of 62 cases examined (90.3%). Notably, the ER+PR– pheno-
type was present in six primary tumours, and in all of these cases
this receptor profile was maintained in the metastatic lesion. There
were no postmenopausal patients with ER+PR+ primary tumours
associated with ER+PR– metastases (data not shown). Taken
together, the data support the view that the receptor phenotype was
stable with progression to a metastatic site and, therefore, that the
lack of PR observed in secondary tumours in postmenopausal
women may be attributed to a greater tendency for PR– primary
tumours to metastasize.
DISCUSSION
There is considerable variability in the reported rates of ER and PR
expression in primary breast cancer, for example in three large
series, ER positivity ranged from 68.8 to 81% and PR from 54 to
70% of cases (Thorpe and Rose, 1986; Wenger et al, 1993; Pichon et
al, 1996). In this cohort, with 62.4% of tumours being ER-positive
and 53.2% expressing PR, the proportion of receptor-positive
tumours was relatively low. A possible explanation for this is that
tumours that are amenable to fine needle aspiration are likely to be
relatively large and an inverse relationship between receptor expres-
sion and tumour size has been reported (Clark et al, 1984; Thorpe
and Rose, 1986; Pichon et al, 1996). In other respects, however, the
characteristics of receptor expression in primary tumours in this
population were typical: older women were more likely to have ER-
positive breast cancer than younger women and, conversely, the rate
of PR positivity was higher in younger women, which is consistent
with other reports (Clark et al, 1984; Thorpe and Rose, 1986;
Romain et al, 1995). Similarly, there was a distinct differential
distribution of the discordant receptor phenotypes with ER+PR–
tumours found principally in older women and ER–PR+ tumours
in younger patients (Osborne et al, 1980; Thorpe, 1988; Bonnier
et al, 1995).
The profile of expression of receptors in secondary tumours was
markedly different than that seen in primary cases. Secondary
tumours were significantly less likely to be ER+ than primary
tumours and in the subgroup of women over 50 years, PR expres-
sion was also significantly less common. Multivariate analysis of
these results revealed a specific lack of PR expression in
secondary tumour deposits compared with primary tumours. This
result reflects the increased prevalence of the ER+PR– phenotype
amongst secondary tumours in postmenopausal patients.
It emerges from this analysis, therefore, that secondary tumour
deposits from postmenopausal patients are unlikely to be PR+
even if ER is present. The failure of secondary tumour deposits to
express receptors, in particular PR, may indicate that primary
tumours that are receptor-negative are more likely to progress and,
therefore, become over-represented in the ‘secondary’ subgroup,
or else that receptor expression is lost as a tumour progresses to a
secondary site, over time or under the influence of therapy.
The issue of the stability of receptor expression with progres-
sion to metastatic sites was addressed by comparing results of ER
and PR assays from simultaneous aspirates performed on primary
tumours and regional lymph node metastases. For ER, the two
assays were concordant in 92.0% of cases. This result is consistent
with reports in the literature that have found the ER status of
primary tumours to be concordant with lymph node or skin
deposits in 81–94% of cases (Hoehn et al, 1979; Jakesz et al, 1985;
Hahnel and Twaddle, 1985; Butler et al, 1989; Kamby et al, 1989;
Kuukasjarvi et al, 1996). Amongst the small number of cases with
discordant results, there was no evidence that ER expression was
lost with metastasis.
Simultaneous assays of PR in primary and regional lymph node
deposits from 65 patients were concordant in 93.8% of cases. All
of the discordant cases were PR+ primary tumours associated with
PR– metastases, indicating that PR is lost upon progression in
some cases. This is consistent with published series, which have
reported concordant PR results in primary tumours and lymph
node or other metastases in 76–91% of cases although the number
of patients in these studies tends to be small (range 18–111, mean
41), (Gross et al, 1984; Jakesz et al, 1985; Alanko, 1985; Butler et
al, 1989; Kuukasjarvi et al, 1996). In most reports it was more
common for the primary tumour to be PR-positive and the metas-
tasis negative than the reverse (Jakesz et al, 1985; Butler et al,
1989; Kuukasjarvi et al, 1996). The available evidence, therefore,
supports the view that PR expression is stable with disease
progression to a metastatic site; however, may be lost in this
process in a small number of cases.
Primary
Secondary
ER+PR+
ER+PR–
ER–PR+
ER–PR–
ER+PR+ ER+PR– ER–PR+ ER–PR–
56
(90%)
19
6
1
1
1
1
2
1
30
Figure 5 Combined ER and PR phenotype of primary tumours and regional
lymph node metastasesPR absence in postmenopausal secondary breast cancer 1569
British Journal of Cancer (1999) 79(9/10), 1564–1571 © Cancer Research Campaign 1999
The combined ER/PR phenotype of the primary tumours and
regional lymph node metastases was concordant in 90.3% of the
62 cases examined. In relation to the relatively high frequency of
the ER+PR– receptor phenotype amongst secondary tumours, it is
noted that there was only one case of an ER+PR+ primary associ-
ated with an ER+PR– metastasis, indicating the ER+PR– cases are
unlikely to evolve from ER+PR+ tumours. There were six cases
where tumour in the breast and lymph node were both ER+PR–,
supporting the view that this phenotype is stable.
The possibility that receptor expression is lost over time has
been examined in a number of studies which have documented
sequential assays from patients who have not been given interval
systemic therapy. These have returned conflicting results;
however, on balance there is little evidence to support a progres-
sive loss of ER expression over time (Webster et al, 1978; Allegra
et al, 1980; Paridaens et al, 1980; Peetz et al, 1982; Hull et al,
1983; Jakesz et al, 1985; Crawford et al, 1987; Spataro et al, 1992;
Kuukasjarvi et al, 1996). There is less information pertaining to
PR, but in three relatively small studies, there was support for the
view that PR expression may be lost over time in some tumours
(Gross et al, 1984; Jakesz et al, 1985; Kuukasjarvi et al, 1996).
Clearly, larger studies are needed to settle this issue but at present
there is consensus in the finding that ER and PR expression are
stable over time in the majority of cases.
It is possible that PR expression may be lost in metastatic
lesions due to the effects of treatment, and there is evidence from a
number of small studies that a transition from receptor-positive to
-negative following endocrine therapy may occur (Hull et al, 1983;
Gross et al, 1984; Nomura et al, 1985; Encarnacion et al, 1993).
Johnston et al (1995) reported a reduction in the rate of ER posi-
tivity from 51% to 29% in 72 breast tumours treated with tamox-
ifen which had acquired resistance or else were resistant de novo.
In 34 cases which relapsed during adjuvant tamoxifen therapy
there was also a significant reduction in PR expression. Prior
systemic therapy may be implicated, therefore, in the tendency for
secondary tumours to be receptor-negative and may explain the
lack of PR in some secondaries from postmenopausal women. Our
observation from simultaneously sampled primary and secondary
lesions, that ER+PR– secondary tumours were mostly associated
with the same receptor profile in the primary implies, however,
that the role, if any, of interval therapy in the prevalence of
ER+PR– secondary tumours is likely to be minor.
The expression of PR is induced by stimulation of the ER by
oestrogen (Horwitz and McGuire, 1978; Clarke, 1993), and there-
fore failure of a proportion of ER+ tumours in postmenopausal
patients to also express PR may simply be a consequence of a low
oestrogen environment providing insufficient stimulation for PR
induction. In this case ER+PR– tumours would not be functionally
different from ER+PR+ cases. There is evidence, however, that,
although plasma oestradiol is relatively low in postmenopausal
women, the hormone is concentrated in breast tissue and is present
in similar levels in pre- and postmenopausal patients (van
Landeghem et al, 1985). Indeed, Saez et al (1978) reported that
plasma levels of oestradiol and progesterone were similar in post-
menopausal patients with ER+PR+ tumours compared with those
with ER+PR– tumours. Further evidence in favour of ER+PR–
breast cancer being distinct is that it can be distinguished clinically
from ER+PR+ disease. The rate of response to endocrine therapy
is much lower, being approximately 38% in ER+PR– cases and
74% in ER+PR+ cases (Horwitz, 1981), and disease-free survival
is also shorter if PR is not expressed (Clark et al, 1983). The
oestrogen-dependent nature of PR expression also raises the possi-
bility that failure of PR expression may be a consequence of aber-
rant ER function. Using PR as a marker of ER function was the
original rationale for measuring PR routinely in breast cancer
(Horwitz et al, 1975), and the increased rate of response to
endocrine therapy when both receptors are present is indirect
support for this hypothesis. The ER+PR– receptor profile amongst
a proportion of tumours may, therefore, signal an association
between ER dysfunction and disease progression.
The absence of PR expression in some breast tumours may also
be due to deletion of the PR gene. The PR gene is located at chro-
mosome 11q22 (Mattei et al, 1988), which is an area of common
loss in breast cancer (Carter et al, 1994; Hampton et al, 1994;
Tomlinson et al, 1996) and an association between loss of
heterozygosity in this region and failure of PR expression in
primary breast cancer has been reported (Tomlinson et al, 1996).
Failure of PR expression may, therefore, reflect a specific pattern
of genetic abnormality in breast cancer and may be a marker of
molecular derangement which is associated with the likelihood of
disease progression.
There are cogent reasons why tumours which fail to express PR
may be biologically distinct and may be associated with an
increased tendency to metastasize. In the normal breast and in
cultured breast cancer cells progesterone has profound effects on
cell growth and function (Graham and Clarke, 1997). One of the
important physiological roles of progesterone is in limiting the
action of oestrogen, which in the normal uterus occurs consequent
to progesterone down-regulation of ER levels and induction of
enzymes which metabolize oestrogen to products with lower
oestrogenic activity (Clarke and Sutherland, 1990). Progestin
down-regulation of ER and inhibition of oestrogenic activity has
also been demonstrated convincingly in cultured breast cancer
cells (Clarke and Sutherland, 1990). Furthermore, more recent
evidence has shown in vitro that one of the isoforms of PR, PR A,
can inhibit the action of ER directly (Chalbos and Galtier, 1994;
McDonnell and Goldman, 1994; Kraus et al, 1995, 1997). Taken
together, an important role of progesterone, and by extension PR,
in breast cancer may be to inhibit the action of oestrogen and
thereby limit its known tumour growth promoting effects. A
tumour which lacks PR would lack this oestrogen-limiting
capacity and this may be clinically associated with an increased
tendency to metastasize.
In summary, a comparison of receptor expression in primary
and secondary breast cancer deposits has shown that secondary
tumours were likely to be receptor-negative and in older women,
PR was uncommonly present even if ER expression was retained.
The lack of PR in secondary lesions could not be attributed to loss
of receptor expression with progression from the primary to a
metastatic site which was consistent with the view that PR-
negative primary tumours were more likely to progress than those
which contain PR. These data suggest that failure of PR expression
may be associated with an aggressive breast tumour phenotype
and may have implications for disease progression. This conclu-
sion is in accordance with the association between PR expression
and both hormone responsiveness and improved survival in breast
cancer. It is unclear, however, whether there is a causal relation-
ship between disease progression and failure of PR expression, or
whether PR negativity is more a marker of molecular aberrations
within a tumour which determine a particular clinical course.
Tumours with the ER+PR– receptor profile, which emerges as an
important subcategory in this analysis, may give insight into themechanism by which PR expression is lost and the pathological
significance of this process.
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